Now Playing
Opinion|Videos|January 6, 2025
Recent Guideline Updates in the Frontline Management of CLL
Dr Niemann provides an overview of the evolving treatment landscape of CLL.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Provide a brief review of the evolving treatment landscape for newly diagnosed CLL.
- Available therapy options (time-limited vs continuous).
- Preference for targeted therapy approaches over conventional chemotherapy.
- Key challenges and unmet needs in the 1L setting.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 that may shake up the CLL treatment paradigm.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
How Are Treatment Intensification and Sequencing Reshaping Care in Prostate Cancer and RCC
4
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
5